2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 585

Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis : in Vivo and in Vitro
Abstract Number: 875

Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Abstract Number: 1608

Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis
Abstract Number: 1421

Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
Abstract Number: 1415

Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE
Abstract Number: 381

Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis
Abstract Number: 1269

Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Abstract Number: 1546

Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Abstract Number: 1270

Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Abstract Number: 484

Effectiveness of Platelet-derived Microparticles for the Diagnosis and Clinical Evaluation of Rheumatoid Arthritis
Abstract Number: 276

Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Abstract Number: 1500

Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Abstract Number: 606

Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort
Abstract Number: 1063

Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].